Cancer

Jaguar Health’s Executive VP Dr. Karen Brunke Joins BIO’s Rare Disease and Orphan Drugs Committee

Jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of short bowel syndrome and microvillus inclusion…

10 months ago

Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013

Investigational New Drug (IND) application submitted to U.S. Food and Drug Administration (FDA) for ELX-02 for the treatment of Alport…

10 months ago

Oncternal Therapeutics Announces its Prostate Cancer Scientific Advisory Board

SAN DIEGO, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the…

10 months ago

INmune Bio Inc. to Present at Baird Global Healthcare Conference and H.C Wainwright 25th Annual Global Investment Conference

Boca Raton, FL, Sept. 07, 2023 (GLOBE NEWSWIRE) -- INmune Bio (NASDAQ: INMB), a clinical-stage immunology company focused on developing…

10 months ago

CLS Americas Presents its TRANBERG™ System for Image-Guided Focal Laser Ablation at Focal Therapy Society 2023 Conference

Minimally Invasive, Outpatient Treatment Designed for Quick Recovery and Low Risk of Unwanted ED and UI Side EffectsWASHINGTON, Sept. 07,…

10 months ago

IMF Medical Student Scholars for Health Equity in Myeloma Present Research at the 2023 NMA Annual Convention & Scientific Assembly

NEW ORLEANS, Sept. 07, 2023 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF), in partnership with the National Medical Association…

10 months ago

Fortress Biotech to Present at H.C. Wainwright 25th Annual Global Investment Conference

MIAMI, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently…

10 months ago

Mustang Bio to Participate in Upcoming September 2023 Investor Conferences

WORCESTER, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on…

10 months ago

Carrick Therapeutics Announces U.S. FDA Clearance of IND for CT7439, a First-In-Class Inhibitor of CDK12/13

DUBLIN, Ireland and BOSTON, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly…

10 months ago